| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cell, Tumor, and Stem Cell Biology |
Departments of 1 Medicine, 2 Pharmacology, and 3 Pediatric Oncology, The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey and 4 The Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts
Requests for reprints: Debabrata Banerjee, Department of Medicine and Pharmacology, The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08903. Phone: 732-235-6458; Fax: 732-235-8181; E-mail: banerjed{at}umdnj.edu.
Key Words: Tumor microenvironment SDF-1 myofibroblast migration differentiation
Carcinoma-associated fibroblasts (CAF) have recently been implicated in important aspects of epithelial solid tumor biology, such as neoplastic progression, tumor growth, angiogenesis, and metastasis. However, neither the source of CAFs nor the differences between CAFs and fibroblasts from nonneoplastic tissue have been well defined. In this study, we show that human bone marrow–derived mesenchymal stem cells (hMSCs) exposed to tumor-conditioned medium (TCM) over a prolonged period of time assume a CAF-like myofibroblastic phenotype. More importantly, these cells exhibit functional properties of CAFs, including sustained expression of stromal-derived factor-1 (SDF-1) and the ability to promote tumor cell growth both in vitro and in an in vivo coimplantation model, and expression of myofibroblast markers, including
-smooth muscle actin and fibroblast surface protein. hMSCs induced to differentiate to a myofibroblast-like phenotype using 5-azacytidine do not promote tumor cell growth as efficiently as hMSCs cultured in TCM nor do they show increased SDF-1 expression. Furthermore, gene expression profiling revealed similarities between TCM-exposed hMSCs and CAFs. Taken together, these data suggest that hMSCs are a source of CAFs and can be used in the modeling of tumor-stroma interactions. To our knowledge, this is the first report showing that hMSCs become activated and resemble carcinoma-associated myofibroblasts on prolonged exposure to conditioned medium from MDAMB231 human breast cancer cells. [Cancer Res 2008;68(11):4331–9]
This article has been cited by other articles:
![]() |
K. H. Schuleri, G. S. Feigenbaum, M. Centola, E. S. Weiss, J. M. Zimmet, J. Turney, J. Kellner, M. M. Zviman, K. E. Hatzistergos, B. Detrick, et al. Autologous mesenchymal stem cells produce reverse remodelling in chronic ischaemic cardiomyopathy Eur. Heart J., November 2, 2009; 30(22): 2722 - 2732. [Abstract] [Full Text] [PDF] |
||||
![]() |
V.-I. Alexaki, G. Notas, V. Pelekanou, M. Kampa, M. Valkanou, P. Theodoropoulos, E. N. Stathopoulos, A. Tsapis, and E. Castanas Adipocytes as Immune Cells: Differential Expression of TWEAK, BAFF, and APRIL and Their Receptors (Fn14, BAFF-R, TACI, and BCMA) at Different Stages of Normal and Pathological Adipose Tissue Development J. Immunol., November 1, 2009; 183(9): 5948 - 5956. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Kutlu, A. G. Kayali, S. Jung, G. Parnaud, D. Baxter, G. Glusman, N. Goodman, L. A. Behie, A. Hayek, and L. Hood Meta-analysis of gene expression in human pancreatic islets after in vitro expansion Physiol Genomics, September 1, 2009; 39(1): 72 - 81. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Eck, A. L. Cote, W. D. Winkelman, and C. E. Brinckerhoff CXCR4 and Matrix Metalloproteinase-1 Are Elevated in Breast Carcinoma-Associated Fibroblasts and in Normal Mammary Fibroblasts Exposed to Factors Secreted by Breast Cancer Cells Mol. Cancer Res., July 1, 2009; 7(7): 1033 - 1044. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Dakhova, M. Ozen, C. J. Creighton, R. Li, G. Ayala, D. Rowley, and M. Ittmann Global Gene Expression Analysis of Reactive Stroma in Prostate Cancer Clin. Cancer Res., June 15, 2009; 15(12): 3979 - 3989. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Ishii, T. Imamura, K. Iguchi, S. Arase, Y. Yoshio, K. Arima, K. Hirano, and Y. Sugimura Evidence that androgen-independent stromal growth factor signals promote androgen-insensitive prostate cancer cell growth in vivo Endocr. Relat. Cancer, June 1, 2009; 16(2): 415 - 428. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. L. Muehlberg, Y.-H. Song, A. Krohn, S. P. Pinilla, L. H. Droll, X. Leng, M. Seidensticker, J. Ricke, A. M. Altman, E. Devarajan, et al. Tissue-resident stem cells promote breast cancer growth and metastasis Carcinogenesis, April 1, 2009; 30(4): 589 - 597. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Maby-El Hajjami, P. Ame-Thomas, C. Pangault, O. Tribut, J. DeVos, R. Jean, N. Bescher, C. Monvoisin, J. Dulong, T. Lamy, et al. Functional Alteration of the Lymphoma Stromal Cell Niche by the Cytokine Context: Role of Indoleamine-2,3 Dioxygenase Cancer Res., April 1, 2009; 69(7): 3228 - 3237. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. B. Coffelt, F. C. Marini, K. Watson, K. J. Zwezdaryk, J. L. Dembinski, H. L. LaMarca, S. L. Tomchuck, K. H. zu Bentrup, E. S. Danka, S. L. Henkle, et al. The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells PNAS, March 10, 2009; 106(10): 3806 - 3811. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Sotgia, F. Del Galdo, M. C. Casimiro, G. Bonuccelli, I. Mercier, D. Whitaker-Menezes, K. M. Daumer, J. Zhou, C. Wang, S. Katiyar, et al. Caveolin-1-/- Null Mammary Stromal Fibroblasts Share Characteristics with Human Breast Cancer-Associated Fibroblasts Am. J. Pathol., March 1, 2009; 174(3): 746 - 761. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. J. Mishra, P. J. Mishra, J. W. Glod, and D. Banerjee Mesenchymal Stem Cells: Flip Side of the Coin Cancer Res., February 15, 2009; 69(4): 1255 - 1258. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. RAMOS, D. DANG, and S. SADLER The Role of the Integrin {alpha}v{beta}6 in Regulating the Epithelial to Mesenchymal Transition in Oral Cancer Anticancer Res, January 1, 2009; 29(1): 125 - 130. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |